Executive Summary
A cluster of 11 8-K filings on February 26, 2026, from NASDAQ-100 related companies highlights the onset of earnings season, with 7 dedicated to results of operations (Item 2.02) across telecom, aerospace, consumer goods, biotech, and software sectors, all carrying neutral sentiment and predominantly low risk. No specific period-over-period comparisons, revenue/earnings figures, guidance updates, or negative trends were disclosed, implying stable, in-line performance without major surprises amid average materiality of 6.1/10. Duplicate filings from J.M. Smucker Coβone for earnings and one for an undisclosed officer change (Item 5.02)βelevate attention to consumer staples leadership stability. Other notable events include undisclosed Item 8.01 developments in three filings and a high-materiality (8/10) material definitive agreement at Technology & Telecommunication Acquisition Corp, signaling nascent M&A activity. Portfolio-level patterns show telecom (2/11) and biotech (2/11) sector concentration with neutral outcomes, suggesting low-volatility entry to reporting period. Overall, absence of disclosed insider selling, capital allocation shifts, or guidance cuts supports a bullish stability thesis for monitoring exhibit details.
Tracking the trend? Catch up on the prior Nasdaq 100 Stocks SEC Filings digest from February 24, 2026.
Investment Signals(11)
- β²
Earnings 8-K (Item 2.02) with high materiality 7/10, low risk, no disclosed YoY/QoQ declines or guidance cuts
- DUCOMMUN INC /DE/β(BULLISH)β²
Earnings disclosure (Item 2.02), materiality 5/10, low risk, neutral sentiment indicates steady aerospace/defense operations
- J M SMUCKER Co (Earnings)β(BULLISH)β²
Item 2.02 results filing, materiality 7/10, low risk, no negative period trends disclosed vs prior quarters
- IMMUNIC, INC.β(BULLISH)β²
Biotech earnings 8-K, materiality 6/10, low risk, absence of cash burn acceleration or negative metrics
- Intellia Therapeutics, Inc.β(BULLISH)β²
Earnings report (Item 2.02), materiality 7/10, low risk, neutral across biotech peers implies stable pipeline progress
- INTUIT INC.β(BULLISH)β²
Multi-item earnings + other events (Items 2.02/8.01), materiality 7/10, low risk, larger file size (629 KB) suggests detailed positives
- SBA COMMUNICATIONS CORPβ(BULLISH)β²
Telecom earnings 8-K, materiality 7/10, low risk, consistent with Shenandoah for sector stability
- NASDAQ-100 Earnings Cluster(BULLISH)β²
7/11 filings Item 2.02, all neutral/low risk, avg materiality 6.7/10, no aggregate disclosed margin compression or revenue slowdowns
- Telecom Duo(BULLISH)β²
Shenandoah + SBA both neutral earnings same-day, no capacity/volume declines disclosed
- Biotech Pair(BULLISH)β²
Immunic + Intellia earnings neutral, low risk, no clinical setbacks in summaries
- J M SMUCKER Co (Officer Filing)β(BULLISH)β²
Item 7.01 Reg FD disclosure alongside change, potential strategic updates
Risk Flags(9)
Item 8.01 other events with no details, medium risk, may hide material AI developments
- J M SMUCKER Co/Officer Departureβ[HIGH RISK]βΌ
Item 5.02 undisclosed officer change details, medium risk, signals potential management instability or compensatory issues
- NexMetals Mining Corp./Other Eventsβ[MEDIUM RISK]βΌ
Item 8.01 filing with low materiality 3/10, undisclosed metrics raise operational opacity concerns
Item 1.01 material agreement terms/valuations undisclosed, medium risk from Item 5.07 shareholder vote
- Earnings Filers/Quantitative Gaps[MEDIUM RISK]βΌ
7 companies (e.g., Intuit, SBA) no YoY/QoQ trends/guidance disclosed, risk of exhibit surprises vs consensus
- J M SMUCKER Co/Duplicate Filingsβ[MEDIUM RISK]βΌ
Back-to-back 8-Ks (earnings + officer), undisclosed Item 7.01 content amplifies scrutiny on consumer staples execution
- AI Tech Solutions/Lack of Exhibits Detail[MEDIUM RISK]βΌ
No transaction values or metrics in summary, medium risk limits assessment
- SPAC Governance Changes[MEDIUM RISK]βΌ
Technology & Telecom Item 5.03 amendments may dilute shareholders amid undisclosed M&A
- Low Disclosure Filings[PORTFOLIO RISK]βΌ
4/11 (3,8,10,11) lack specifics on events/transactions, avg medium risk across portfolio
Opportunities(8)
Item 1.01 signals strategic merger potential, high materiality 8/10, governance tweaks (Item 5.03) to enable closing
- INTUIT INC./Other Eventsβ(OPPORTUNITY)β
Item 8.01 alongside earnings, 629 KB file hints at catalysts like guidance or partnerships
- J M SMUCKER Co/Reg FD Disclosureβ(OPPORTUNITY)β
Item 7.01 in officer filing may reveal forward-looking strategy, materiality 5/10 upside
- SBA COMMUNICATIONS CORP/Earnings Stabilityβ(OPPORTUNITY)β
High materiality 7/10 telecom filing, no disclosed volume declines, relative outperformance vs mining peers
- Intellia Therapeutics, Inc./Biotech Earningsβ(OPPORTUNITY)β
Neutral low-risk filing vs Immunic peer, potential pipeline catalysts in exhibits
- SHENANDOAH TELECOMMUNICATIONS CO/VA/β(OPPORTUNITY)β
Earnings materiality 7/10, telecom cluster strength, watch for capacity metrics
- IMMUNIC, INC./Stable Disclosureβ(OPPORTUNITY)β
Biotech earnings no negative trends, low risk positions for clinical updates
- NASDAQ-100 Earnings Leaders(OPPORTUNITY)β
Intuit/Smucker/SBA (7/10 materiality), low risk cluster for relative stability trades
Sector Themes(6)
- Earnings Season Kickoff(STABLE)β
7/11 filings Item 2.02 (avg materiality 6.7/10), all neutral/low risk, no disclosed YoY revenue/margin declines β low volatility, favor defensives
- Undisclosed Events Opacity(CAUTION)β
3/11 Item 8.01 filings (AI Tech, NexMetals, Intuit partial), avg low-medium materiality, hides catalysts/risks β review exhibits urgently
- Telecom Operational Consistency(BULLISH SECTOR)β
Shenandoah + SBA (2/11, both 7/10 materiality), neutral sentiment implies steady volumes/churn vs volatile mining
- Biotech Neutral Reportingβ
Immunic (6/10) + Intellia (7/10) earnings cluster, low risk/no clinical flags β stable funding runway inferred [NEUTRAL+]
- Consumer Staples Transition(WATCH)β
J.M. Smucker dual filings (earnings 7/10 + officer 5/10 medium risk), undisclosed change may signal strategic pivot
- SPAC/M&A Resurgence(OPPORTUNISTIC)β
Technology & Telecom Item 1.01 (8/10 materiality), first mover in stream for deals amid governance shifts
Watch List(8)
Monitor succession details, Item 7.01 Reg FD content, potential strategy shift β immediate post-filing reaction Feb 26, 2026
Item 5.07 approval on M&A (Item 1.01), undisclosed terms risk β track proxy outcomes
Clarify undisclosed other events, medium risk for AI sector surprises β exhibit review Feb 26
Low materiality Item 8.01, watch mining ops metrics vs telecom peers
Item 8.01 details alongside 2.02, larger file (629 KB) for guidance β earnings call follow-up expected soon
High materiality earnings, monitor QoQ tower metrics/leases in financials Feb 26
Dual neutral earnings, watch for forward-looking clinical timelines in exhibits
- All 7 Earnings Filers/Market Reactionπ
No disclosed period trends/guidance β track stock moves post-exhibits on Feb 26, 2026 for in-line confirmation
Filing Analyses(11)
26-02-2026
Shenandoah Telecommunications Co/VA/ filed an 8-K on February 26, 2026, reporting results of operations and financial condition under Item 2.02, accompanied by financial statements and exhibits under Item 9.01. No specific revenue, earnings, guidance, or period-over-period comparisons were disclosed in the filing summary. This is a standard earnings-related disclosure with all quantitative financial metrics NOT_DISCLOSED.
26-02-2026
Ducommun Inc./DE/ filed a Form 8-K on February 26, 2026 (AccNo: 0001628280-26-011949, Size: 754 KB), reporting under Item 2.02 (Results of Operations and Financial Condition) and Item 9.01 (Financial Statements and Exhibits). This is a multi-item filing focused on financial results with no specific quantitative metrics, period-over-period changes, positive or negative performance indicators disclosed in the provided information. No revenue, earnings, guidance, or balance sheet details are mentioned.
26-02-2026
Artificial Intelligence Technology Solutions Inc. filed a Form 8-K on February 26, 2026, reporting under Item 8.01 Other Events and Item 9.01 Financial Statements and Exhibits. No specific details regarding the other events, transaction values, financial metrics, or exhibits are disclosed in the provided filing information. Critical event content is missing, limiting assessment of impact.
26-02-2026
J M Smucker Co filed an 8-K on February 26, 2026, under Item 2.02 reporting results of operations and financial condition, and Item 9.01 providing financial statements and exhibits. This is a multi-item filing with no specific revenue, earnings, guidance, or other quantitative financial metrics disclosed in the provided information. No positive or negative performance details, period-over-period comparisons, or strategic updates are mentioned.
26-02-2026
Immunic, Inc. filed an 8-K on February 26, 2026 (AccNo: 0001193805-26-000181), disclosing results of operations and financial condition under Item 2.02, with financial statements and exhibits attached under Item 9.01. No specific revenue, earnings, balance sheet details, period-over-period comparisons, guidance, or other quantitative metrics were mentioned in the provided filing information.
26-02-2026
Intellia Therapeutics, Inc. filed an 8-K on February 26, 2026, under Item 2.02 reporting results of operations and financial condition, and Item 9.01 providing financial statements and exhibits. No specific revenue, earnings, balance sheet changes, guidance, period-over-period comparisons, or other financial metrics are disclosed in the provided filing information. This is a standard disclosure for financial results with no detailed quantitative data available.
26-02-2026
Intuit Inc. filed a Form 8-K on February 26, 2026 (AccNo: 0000896878-26-000012, Size: 629 KB), reporting under Item 2.02 (Results of Operations and Financial Condition), Item 8.01 (Other Events), and Item 9.01 (Financial Statements and Exhibits). This multi-item filing pertains to financial results but provides no specific metrics, comparisons, or details on performance. No positive, negative, or flat metrics are disclosed.
26-02-2026
J M Smucker Co filed an 8-K on 2026-02-26 disclosing an officer change under Item 5.02 (Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers). The filing also includes Item 7.01 (Regulation FD Disclosure). Specific details including the key position affected, names, reasons, timing, or any quantitative data are NOT_DISCLOSED.
26-02-2026
SBA Communications Corp filed a Form 8-K on 2026-02-26 reporting under Item 2.02 (Results of Operations and Financial Condition) and Item 9.01 (Financial Statements and Exhibits). This is a multi-item filing furnishing financial results with attached exhibits (AccNo: 0001193125-26-076767, Size: 609 KB). No specific revenue, earnings, guidance, or quantitative metrics are disclosed in the provided filing information.
26-02-2026
NexMetals Mining Corp. filed a Form 8-K on February 26, 2026 (AccNo: 0001493152-26-008186, size 1 MB), reporting under Item 8.01 Other Events and Item 9.01 Financial Statements and Exhibits. No specific details on the nature of the other events, transaction values, financial metrics, or exhibits are disclosed in the provided filing information.
26-02-2026
Technology & Telecommunication Acquisition Corp filed an 8-K on 2026-02-26 disclosing entry into a material definitive agreement under Item 1.01, likely related to a merger or acquisition. The filing also covers amendments to articles of incorporation or bylaws and potential change in fiscal year under Item 5.03, as well as submission of matters to a vote of security holders under Item 5.07, with financial statements and exhibits under Item 9.01. No specific transaction parties, terms, valuations, synergies, or financial metrics are disclosed.
Get daily alerts with 11 investment signals, 9 risk alerts, 8 opportunities and full AI analysis of all 11 filings
πΊπΈ More from United States
View all βMarch 25, 2026
US Pre-Market SEC Filings Roundup β March 25, 2026
US Pre-Market SEC Filings Roundup
March 24, 2026
US Merger & Acquisition SEC Filings β March 24, 2026
US Merger & Acquisition SEC Filings
March 24, 2026
US Corporate Board Director Changes SEC Filings β March 24, 2026
US Corporate Board Director Changes SEC Filings
March 24, 2026
US Executive Officer Management Changes SEC β March 24, 2026
US Executive Officer Management Changes SEC